SUPARTZ FX has a wealth of experience around the world

  • 300 million injections and more than 20 years of use worldwide (19)
  • More than 20 prospective clinical trials in the published literature (18)
  • SUPARTZ FX is demonstrated safe for repeat injection cycles (20)


SUPARTZ FX has demonstrated effectiveness through 6 months (16)


SUPARTZ FX offers a safety profile similar to saline placebo

  • Comparable rates of adverse events following SUPARTZ FX versus saline placebo (12,13)
  • Discontinuation rates due to adverse events were 1.8% for SUPARTZ and 3.2% for placebo (12)
  • No reports of pseudoseptic reactions in the scientific literature* (18)


SUPARTZ FX contains minimal impurities

  • A study of impurities in HA products found that SUPARTZ FX has less protein content than others (31)
  • SUPARTZ FX also had significantly less bacteria endotoxin content and significantly less nucleic acids/DNA content compared with other HA products (31)


*Does not include current prescribing experience.
All trademarks are the properties of their respective companies.

SUPARTZ FX is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. You should not use SUPARTZ FX if you have infections or skin diseases at the injection site or allergies to poultry products. SUPARTZ FX is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site. Full prescribing information can be found here or by contacting customer service at